Elements for a Public Summary

Similar documents
Summary of Treatment Benefits Page 72 of 111. Page 72

An overview of the disease epidemiology of the four indications of levothyroxine is provided in this section.

ELTROXIN thyroxine (as anhydrous levothyroxine sodium) 50 micrograms, 100 micrograms tablets

Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Elements for a Public Summary

Elements for a Public Summary

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider

Thyroid Gland. Patient Information

PATIENT INFORMATION LEAFLET

Zerlinda (MRP DK/H/2265/001)

Elements for a public summary

Elements for a Public Summary

THYROID AWARENESS. By: Karen Carbone. January is thyroid awareness month. At least 30 million Americans

Nocturnal polyuria has been linked to abnormalities of the daily rhythm of (circadian rhythmic) release of naturally occurring antidiuretic hormone.

Summary of the Risk Management Plan (RMP) V. 1.6, July 2017 for BAVENCIO. Avelumab 200 mg/10 ml. Concentrate for Solution for Infusion

Elements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) MODAFINIL ORION 100 MG, 200 MG Tablets ORION CORPORATION DATE: , VERSION 1.

THE THYROID GLAND AND YOUR HEALTH

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS. Treatment Journal. H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis.

Talking about your treatment. A guide to the conversations you may have before starting LEMTRADA

Elements for a Public Summary

Acthar TREATMENT JOURNAL

(sunitinib malate) for Kidney Cancer

Elements for a Public Summary

LESSON ASSIGNMENT. Thyroid, Antithyroid, and Parathyroid Preparations. After completing this lesson, you should be able to:

Diseases in which appear swelling, redness, pain and heat; aspects of the immune system (Inflammatory and immunologic conditions-imid)

Slide notes: This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications,

Who is this leaflet for? What is hyperthyroidism? What is the thyroid gland? What causes hyperthyroidism? How is hyperthyroidism diagnosed?

Ezetimib Stada 10 mg tablets

For the Patient: USMAVPEM

Elements for a Public Summary

PACKAGE LEAFLET: INFORMATION FOR THE USER

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

Overview of reports of adverse drug reactions associated with changes of the package of Thyrax (levothyroxine) from a bottle to a blister

For the Patient: USMAVFIPI

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:

Elements for a public summary

Your Thyroid By Lawrence C. F Wood M.D., Chester Ridgway READ ONLINE

Package leaflet: Information for the patient. Metopirone 250 mg Capsules Metyrapone

Overview of disease epidemiology

Elements for a public summary

Patient Information ALVESCO [ael- ves-koʊ] (ciclesonide) Inhalation Aerosol. Do not use your ALVESCO Inhalation Aerosol near heat or an open flame.

Summary of the risk management plan (RMP) for Kyprolis (carfilzomib)

AMGEVITA (adalimumab)

Summary of the risk management plan (RMP) for Ketoconazole HRA (ketoconazole)

Atenomel 25mg Tablets Atenomel 50mg Tablets Atenomel 100mg Tablets

Package leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide

OLANZAPINE-SYNTHON Olanzapine benzoate

Amarillo Surgical Group Doctor: Date:

Opdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?

Summary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin)

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cinfalair 4 mg chewable tablets

For males: use effective birth control during your treatment with INLYTA. Talk to your doctor about birth control methods.

Olanzapine generichealth tablets Olanzapine benzoate

A study conducted in Norway found the combined estimate for panic and generalized anxiety disorder was 1.10 per 1,000 person-years.

MEDICATION GUIDE SUTENT

TREANA 5mg and 10mg Film-coated Tablets

Pregabalin Aristo Version: RMP-Pregabalin0

Discussing TECENTRIQ (atezolizumab) with your healthcare team

Important safety information to minimise the risk of immune-related adverse reactions

Understanding thyroid function tests. Dr. Colette George

Package leaflet: Information for the patient. Tenoretic 100 mg/25 mg film coated tablets. atenolol 100 mg, chlortalidone 25 mg

Elements for a Public Summary

Elements for a public summary

Nivolumab. Nivolumab

Daunorubicin daw-no-roo-bih-sin

Vildagliptin belongs to a group of medicines called oral antidiabetics.

For the Patient: USMAVNIV

Package leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe

NEO-MERCAZOLE Carbimazole 5 mg tablets

Desmopressin Version 2.0. Public summary of the Risk Management Plan

2. What you need to know before you take Tenormin

Litij Karbonat 300 mg tablets

Questionnaire for Lipedema Patients

For the Patient: ULUAVPMB

If you are allergic to octreotide or any of the ingredients of this medicine (listed in section 6).

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. LEMTRADA (alemtuzumab)

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.

Inlyta (axitinib) for Kidney Cancer

New Patient Medical History Intake Form

Patient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents

This leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information.

Consumer Medicine Information

Thyroid Disorders. January 2019

VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits

Package leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets. Nicotine

The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

SYNACTHEN DEPOT i.m. tetracosactide hexaacetate

VI.2 Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

Boots Decongestant Tablets with Paracetamol (Paracetamol, Pseudoephedrine Hydrochloride)

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET

Please answer all questions in blue or black ink by filling in the blank or circling. SOCIAL HISTORY

Package leaflet: Information for the user. CYPROSTAT 50 mg tablet cyproterone acetate

Transcription:

VI.2 Elements for a Public Summary <Product Name> 25 microgram tablets <Product Name> 50 microgram tablets <Product Name> 75 microgram tablets <Product Name> 100 microgram tablets <Product Name> 125 microgram tablets <Product Name> 150 microgram tablets <Product Name> 175 microgram tablets <Product Name> 200 microgram tablets VI.2.1 Overview of disease epidemiology Hypothyroidism is a disorder in which thyroid gland, a small gland in the neck, is underactive and does therefore not produce enough thyroid hormones. These hormones are called triiodothyronine (T3) and thyroxine (T4). Main symptomps include tiredness, weight gain, depression, dry skin and hair and being sensitive to the cold. A blood test needs to be performed for hypothyroidism to be diagnosed. Prevalence of hypothyroidism worldwide is estimated to be between 2 and 4 in 1000 people. Hypothyroidism is more common in women, although men can be affected as well. Typical treatment involves daily hormonereplacement tablets, called levothyroxine (such as <Product Name>), to increase the thyroxine levels. Most patients require treatment for the rest of their life but this varies greatly. Levothyroxine (such as <Product Name>) may also be used when over-treatment of high thyorid hormone levels (hyperthyroidism) leads to too low levels of thyroid hormones (a pardoxical reaction). Thyroid suppression testing is used to investigate the levels of the thyroid hormones. Triiodothyronine (T3) and thyroxine (T4), as well as thyroid-stimulating hormone (TSH) levels, are tested. Levothyroxine (such as <Product Name>) may be used to determine TSH levels. Patients will receive a dose of levothyroxine and their change in T4 and TSH levels will then be measured. Euthyroid goitre is a swollen thyroid gland which usually manifests as a lump in the neck. It is a symptom of an over- or an under-active thyorid gland, thyroid cancer or idodine deficiency. Tretment will depend on the cause and on the size the lump. If the lump is small and deemed as unproblematic, it may just be monitored at first. If goitre is caused by the lack of thyroid gland hormones, it may be treated with daily hormone-replacement tablets, called levothyroxine (such as <Product Name>), to increase the thyroxine levels. Surgery and radioidoine treatment may be used to remove to goitre if it gets too large and problematic. Levothyroxine (such as <Product Name>) may also be used to prevent relapse of goitre after surgery. Thyroid cancer is cancer of the thyorid gland, a small gland in the neck, which usually manifests as a lump/swelling in the neck. However, a lump in the thyroid does not necessarily mean that you have thyroid cancer - only around 1 in 20 thyroid lumps are cancerous. A sore throat or voice changes are additional symptoms which may occur. Thyorid cancer is a rare cancer, occuring in 1-3% of cancer cases. It usually affectes people between 35 and 39 and those over 70 years of age. Women are 2-3 times more likely to develop thyroid cancer than men. Between 80% and 90% of patients with thyorid cancer will have a normal lifespan.treatment varies but usually includes levothyroxine (such as STADA Arzneimittel AG C O N F I D E N T I A L Page 23 of 47

<Product Name>) to suppress cancer growth, surgery to remove the thyroid gland and radiotherapy. VI.2.2 Summary of treatment benefits Levothyroxine, the active substance in <Product Name>, is a synthetic thyroid hormone for the treatment of diseases and dysfunctions of the thyroid gland. It has the same effect as the naturally occurring thyroid hormones. <Product Name> 25-200 microgram is used to treat benign goitre in patients with normal thyroid function, to prevent recurrence of goitre after surgery, to replace natural thyroid hormones, when your thyroid gland does not produce enough, to suppress tumour growth in patients with thyroid cancer. <Product Name> 25-100 microgram can also be used to balance thyroid hormone levels, when overproduction of hormones is treated with antithyroid medicines. <Product Name> 100/150/200 microgram may also be used in the testing of your thyroid function. VI.2.3 Unknowns relating to treatment benefits None. STADA Arzneimittel AG C O N F I D E N T I A L Page 24 of 47

VI.2.4 Summary of safety concerns Important identified risks Risk What is known Preventability Allergic reactions Condition occuring due to over-active thyroid (Thyrotoxicosis) Serious condition caused by insufficient cortisol hormone levels (Adrenal crisis) Hypersensitivity reactions including rash, itching, shortness of breath, joint pain, general discomfort and swelling may occur with <Product Name> use. Pateinst with an over-active thyroid (thyrotoxicosis), i.e. those in who have high levels of thyroid hormones, should not be taking <Product Name>. <Product Name> increases thyroid hormone levels and will therefore further elevate these is patients with overactive thyroid. <Product Name> is contraindicated in patients with uncorrected adrenal insufficiency (condition in which the adrenal glands do not produce enough steroid hormones, primarily cortisol), as excessive thyroid hormones from <Product Inform your doctor if you have any allergies. Always take this medicine as prescribed by your doctor and as indicated in the Package Leaflet. This will minimise the risk of developing adverse drug reactions. Contact your doctor if you unexplained swelling rash shortness of breath joint pain with overactive thyroid. Contact your doctor if you hyperactivity mood swings difficulty sleeping feeling tired all the time muscle weakness sensitivity to heat and excess sweating unexplained or unexpected weight loss with adrenal insufficiency. Contact your doctor immediatelly if you STADA Arzneimittel AG C O N F I D E N T I A L Page 25 of 47

Cardiovascular disorders Name> may precipitate an acute adrenal crisis (a serious condition caused by insufficient cortisol levels) by increasing the elimination of steroids from the body. In patients with cardiovascular problems (e.g. arrhythmias, cardiac failure), increase in thyroid hormones as a result of over-treatment with <Product Name> must be avoided, as it may lead to worsening of these pre-existing cardiovascular problems. nausea or abdominal pain. vomiting. fever. joint pain. loss of appetite. dramatic changes in blood pressure. weakness. chills. with any cardiac problems. Your doctor will perform regular checks of your thyroid hormone levels. Contact your doctor immediatelly if you rapid heart rate shortness of breath weakness. swelling in your legs, ankles and feet (or worsening of the same). Important potential risks Risk Seizures in patients with known history of epilepsy What is known (Including reason why it is considered a potential risk) Patients treated with <Product Name> who have previously been diagnosed with epilepsy may be at an increased risk of developing seizures (fits). Care is required when levothyroxine is administered to patients with known history of epilepsy. Seizures (fits) have been reported rarely in association with the initiation of levothyroxine sodium therapy, and may be related to the effect of thyroid hormone on seizure threshold. Missing information Risk What is known STADA Arzneimittel AG C O N F I D E N T I A L Page 26 of 47

None N/A VI.2.5 Summary of risk minimisation measures by safety concern All medicines have a Summary of Product Characteristics (SPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures. This medicine has no additional risk minimisation measures. VI.2.6 Planned post authorisation development plan No post-authorisation studies have been imposed or are planned. VI.2.7 Summary of changes to the Risk Management Plan over time Not applicable STADA Arzneimittel AG C O N F I D E N T I A L Page 27 of 47